BioCryst focuses on rare diseases like Hereditary Angioedema (HAE), and Dr. Helen Thackray led R&D efforts at the company.
1 report, 1 independent
Updated Aug 11
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
BioCryst focuses on rare diseases like Hereditary Angioedema (HAE), and Dr. Helen Thackray led R&D efforts at the company.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- AscellaHealth supports rare disease manufacturers, while BioCryst Pharmaceuticals details its leadership structure with Quill, Gayer, and Oldham.Sub-event
- ORLADEYO has seen significant revenue growth, and new treatments are being evaluated for their potential impact on the demand for HAE sufferers.Sub-event
BioCryst focuses on HAE, and Dr. Thackray led R&D efforts there.1 source
Keep exploring
The entities involved
-
BioCryst Pharmaceuticals
American pharmaceutical company
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswireBioCryst Announces Departure of Dr. Helen Thackray RESEARCH TRIANGLE PARK, N.C., Aug. 11, 2025 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that Dr. Helen Thackra